Kestrel Therapeutics Gains FDA Fast Track for KST-6051
WATERTOWN, Mass. — September 15, 2026 Kestrel Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has...
Precision Oncology
Advertisement
Summit Therapeutics Reports Ivonescimab Survival Data at WCLC
Los Angeles, California, September 15, 2026 Summit Therapeutics has announced positive overall survival results from the Phase 3 HARMONi-2...
Taiho Oncology’s Zipalertinib Improves PFS in EGFR Lung Cancer
Princeton, New Jersey, September 15, 2026 Taiho Oncology has announced positive results from the REZILIENT3 Phase 3 trial, showing...
Revolution Medicines Gains FDA Breakthrough Designation for RASONQUE
REDWOOD CITY, Calif. — September 14, 2026 Revolution Medicines, Inc. announced that the U.S. Food and Drug Administration (FDA)...
J&J’s RYBREVANT Shows Longest OS in EGFR Lung Cancer
Raritan, New Jersey, U.S., September 14, 2026 Johnson & Johnson announced new overall survival data from the Phase III...
Advertisements
Curium Gains FDA Approval for BEXLUTRY in GEP-NETs
BOSTON, Mass. — September 14, 2026 Curium™ announced that the U.S. Food and Drug Administration (FDA) has approved its...
AstraZeneca’s Tagrisso Delivers 8-Year Survival in Lung Cancer
Wilmington, Delaware, U.S., September 14, 2026 AstraZeneca announced updated results from the Phase III ADAURA trial, showing sustained long-term...
Crossbow Therapeutics Doses First Patient in CBX-663 Phase 1
CAMBRIDGE, Mass. — September 9, 2026 Crossbow Therapeutics, Inc. announced dosing of the first participant in the Phase 1...
TwoStep Therapeutics Secures $62.5M and FDA IND Clearance
SAN CARLOS, Calif. — September 9, 2026 TwoStep Therapeutics announced an oversubscribed $62.5 million Series A financing alongside U.S....
Bayer Wins FDA Accelerated Approval for Sevabertinib
BERLIN — September 9, 2026 Bayer announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval...
Advertisement
